HC Wainwright Analysts Cut Earnings Estimates for BriaCell Therapeutics Corp. (NASDAQ:BCTX)

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Equities research analysts at HC Wainwright lowered their FY2025 EPS estimates for BriaCell Therapeutics in a report released on Thursday, October 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.58) per share for the year, down from their previous forecast of ($0.26). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.19) EPS and FY2029 earnings at ($0.11) EPS.

BriaCell Therapeutics Trading Up 0.9 %

Shares of BriaCell Therapeutics stock opened at $1.08 on Monday. The company has a fifty day simple moving average of $0.72 and a 200-day simple moving average of $1.35. The stock has a market cap of $19.75 million, a price-to-earnings ratio of -0.86 and a beta of 1.34. BriaCell Therapeutics has a 12-month low of $0.46 and a 12-month high of $6.10.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. K.J. Harrison & Partners Inc boosted its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 7.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,044 shares of the company’s stock after buying an additional 6,329 shares during the period. K.J. Harrison & Partners Inc owned 0.54% of BriaCell Therapeutics worth $249,000 as of its most recent SEC filing. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.